Syngene International Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 7,210

Employees

  • Stock Symbol
  • 539268

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $4.68
  • (As of Thursday Closing)

Syngene International General Information

Description

Syngene International Ltd is a contract research, development and manufacturing organization (CRDMO) providing integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. Its business divisions include Discovery Services, Translational & Clinical Research, Dedicated Centers, and Contract Development and Manufacturing Services. Its services cover lead generation, medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development, and clinical development services. The Company operates in a single segment of contract research and manufacturing services, with the majority of its revenue derived from the USA.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • Biocon Park, SEZ, Bommasandra Industrial Area Phase IV
  • Jigani Link Road
  • Bangalore, Karnataka 560099
  • India
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Other Pharmaceuticals and Biotechnology
Stock Exchange
BOM
Vertical(s)
Corporate Office
  • Biocon Park, SEZ, Bommasandra Industrial Area Phase IV
  • Jigani Link Road
  • Bangalore, Karnataka 560099
  • India

Syngene International Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Syngene International Stock Performance

As of 19-Nov-2026, Syngene International’s stock price is $4.68. Its current market cap is $1.88B with 402M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.68 $4.65 $3.56 - $7.52 $1.88B 402M 143K $0.05

Syngene International Financials Summary

As of 30-Sep-2026, Syngene International has a trailing 12-month revenue of $380M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 1,439,973 1,596,296 3,353,495 3,292,046
Revenue 379,890 408,618 415,435 407,014
EBITDA 80,340 95,888 128,410 122,702
Net Income 20,071 35,840 58,682 61,605
Total Assets 693,224 747,695 794,477 737,659
Total Debt 52,826 48,584 67,560 66,576
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Syngene International Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Syngene International‘s full profile, request access.

Request a free trial

Syngene International Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Syngene International Ltd is a contract research, development and manufacturing organization (CRDMO) providing integrate
Biotechnology
Bangalore, India
7,210 As of 2026

Beijing, China
 

Navi Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Syngene International Competitors (51)

One of Syngene International’s 51 competitors is Pharmaron, a Formerly VC-backed company based in Beijing, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pharmaron Formerly VC-backed Beijing, China
Reliance Life Sciences Corporation Navi Mumbai, India
Eurofins Scientific Corporation Luxembourg, Luxembourg
WuXi AppTec Formerly PE-Backed Shanghai, China
Lupin Corporation Mumbai, India
You’re viewing 5 of 51 competitors. Get the full list »

Syngene International Patents

Syngene International Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240158394-A1 Nek7 inhibitors Pending 14-Sep-2022
WO-2022241265-A1 Inhibitors of the menin-mll interaction Inactive 14-May-2021
US-11718601-B2 Pyridinyl substituted oxoisoindoline compounds Active 06-Apr-2021
US-20220324840-A1 Pyridinyl substituted oxoisoindoline compounds Active 06-Apr-2021
US-11572350-B1 Benzothia(di)azepine compounds and their use as bile acid modulators Active 04-Dec-2020 C07D285/36
To view Syngene International’s complete patent history, request access »

Syngene International Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Syngene International Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Syngene International‘s full profile, request access.

Request a free trial

Syngene International Investments (6)

Syngene International’s most recent deal was a Secondary Transaction - Private with O2 Renewable Energy V for . The deal was made on 16-Jan-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
O2 Renewable Energy V 16-Jan-2026 Secondary Transaction - Private Other Energy Services
Emergent BioSolutions (Drug Substance Manufacturing Facility in Baltimore, Maryland ) 19-Mar-2025 Corporate Asset Purchase Buildings and Property
Stelis Biopharma (Biologics Manufacturing Unit 3) 01-Dec-2023 Corporate Asset Purchase Other Pharmaceuticals and Biotechnology
O2 Renewable Energy II 27-Aug-2022 Secondary Transaction - Private Energy Production
AMPYR Renewable Energy Resources Eleven 12-Jul-2022 Secondary Transaction - Private Special Purpose Acquisition Company (SPAC)
You’re viewing 5 of 6 investments. Get the full list »

Syngene International ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

14.66 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Laboratory Equipment and Services

Subindustry

of 67

Rank

Percentile

To view Syngene International’s complete esg history, request access »

Syngene International FAQs

  • When was Syngene International founded?

    Syngene International was founded in 1993.

  • Where is Syngene International headquartered?

    Syngene International is headquartered in Bangalore, India.

  • What is the size of Syngene International?

    Syngene International has 7,210 total employees.

  • What industry is Syngene International in?

    Syngene International’s primary industry is Biotechnology.

  • Is Syngene International a private or public company?

    Syngene International is a Public company.

  • What is Syngene International’s stock symbol?

    The ticker symbol for Syngene International is 539268.

  • What is the current stock price of Syngene International?

    As of 19-Nov-2026 the stock price of Syngene International is $4.68.

  • What is the current market cap of Syngene International?

    The current market capitalization of Syngene International is $1.88B.

  • What is Syngene International’s current revenue?

    The trailing twelve month revenue for Syngene International is $380M.

  • Who are Syngene International’s competitors?

    Pharmaron, Reliance Life Sciences, Eurofins Scientific, WuXi AppTec, and Lupin are some of the 51 competitors of Syngene International.

  • What is Syngene International’s annual earnings per share (EPS)?

    Syngene International’s EPS for 12 months was $0.05.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process